The involvement of the ErbB signaling pathway is not surprising – it is well-known that the ErbB protein family or epidermal growth factor receptor (EGFR) family, especially ErbB-2 (HER-2), is often over-expressed with aggressive clinical behavior and poor outcome in patients with breast cancer [22]. Here, EGFR is linked to breast carcinoma.